61. In paragraph 4(2) of Schedule 5 (procedural provisions relating to the refusal or amendment of, or imposition of conditions relating to, clinical trial authorisations and the suspension or termination of clinical trials)—U.K.
(a)in sub-paragraph (a), for paragraphs (i) to (iii) substitute—
“(i)the Commission on Human Medicines,
(ii)an expert committee appointed by the licensing authority,
(iii)an expert advisory group within the meaning of regulation 14 of the 2012 Regulations,
(iv)the British Pharmacopoeia Commission referred to in regulation 11 of the 2012 Regulations, or any of its sub-committees,
(v)the Medicines Commission formerly established under section 2 of the Act, or any of its committees,
(vi)the Advisory Board on the Registration of Homoeopathic Products formerly established under section 4 of the Act, or any of its sub-committees, or
(vii)the Herbal Medicines Advisory Committee formerly established under section 4 of the Act, or any of its sub-committees, and”; and
(b)in sub-paragraph (b) after “Crown” insert “ , the Scottish Ministers, the Welsh Ministers or a Northern Ireland Minister ”.